{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T11:00:12Z","timestamp":1761649212487,"version":"3.44.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"am","delay-in-days":334,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018155","name":"The Price Family Foundation Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018155","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.bbr.2023.114614","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T11:39:34Z","timestamp":1691667574000},"page":"114614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["NU-1223, a simplified analog of alstonine, with 5-HT2cR agonist-like activity, rescues memory deficit and positive and negative symptoms in subchronic phencyclidine mouse model of schizophrenia"],"prefix":"10.1016","volume":"454","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2382-258X","authenticated-orcid":false,"given":"Lakshmi","family":"Rajagopal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanaz","family":"Mahjour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chelsea A.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Elzokaky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam J.","family":"Csakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meghan J.","family":"Orr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Scheidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert Y.","family":"Meltzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bbr.2023.114614_bib1","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(25)20710-8","article-title":"Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values","volume":"251","author":"Meltzer","year":"1989","journal-title":"J. Pharm. Exp. Ther."},{"issue":"4","key":"10.1016\/j.bbr.2023.114614_bib2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd1346","article-title":"Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia","volume":"3","author":"Roth","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9","key":"10.1016\/j.bbr.2023.114614_bib3","first-page":"525","article-title":"Lorcaserin (Belviq): a selective serotonin 5-HT2C agonist in the treatment of obesity","volume":"38","author":"Gustafson","year":"2013","journal-title":"P T"},{"issue":"5","key":"10.1016\/j.bbr.2023.114614_bib4","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2174\/138161210790361416","article-title":"Unraveling monoamine receptors involved in the action of typical and atypical antipsychotics on glutamatergic and serotonergic transmission in prefrontal cortex","volume":"16","author":"Lopez-Gil","year":"2010","journal-title":"Curr. Pharm. Des."},{"issue":"4","key":"10.1016\/j.bbr.2023.114614_bib5","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/0269881113512909","article-title":"Reviewing the ketamine model for schizophrenia","volume":"28","author":"Frohlich","year":"2014","journal-title":"J. Psychopharmacol."},{"issue":"21\u201322","key":"10.1016\/j.bbr.2023.114614_bib6","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1007\/s00213-015-3954-6","article-title":"The subchronic phencyclidine rat model: relevance for the assessment of novel therapeutics for cognitive impairment associated with schizophrenia","volume":"232","author":"Janhunen","year":"2015","journal-title":"Psychopharmacol. (Berl.)"},{"issue":"4","key":"10.1016\/j.bbr.2023.114614_bib7","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0893-133X(01)00243-3","article-title":"Effects of ketamine in normal and schizophrenic volunteers","volume":"25","author":"Lahti","year":"2001","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1016\/j.bbr.2023.114614_bib8","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1017\/S1461145713000928","article-title":"Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia","volume":"16","author":"Meltzer","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.bbr.2023.114614_bib9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.pharmthera.2010.07.004","article-title":"Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism","volume":"128","author":"Neill","year":"2010","journal-title":"Pharm. Ther."},{"issue":"4","key":"10.1016\/j.bbr.2023.114614_bib10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1358\/mf.2007.29.4.1075358","article-title":"Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis","volume":"29","author":"Enomoto","year":"2007","journal-title":"Methods Find. Exp. Clin. Pharm."},{"key":"10.1016\/j.bbr.2023.114614_bib11","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/7854_2015_403","article-title":"Postnatal phencyclidine (PCP) as a neurodevelopmental animal model of schizophrenia pathophysiology and symptomatology: a review","volume":"29","author":"Grayson","year":"2016","journal-title":"Curr. Top. Behav. Neurosci."},{"issue":"2","key":"10.1016\/j.bbr.2023.114614_bib12","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1124\/jpet.109.156349","article-title":"Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist","volume":"332","author":"Snigdha","year":"2010","journal-title":"J. Pharm. Exp. Ther."},{"issue":"10","key":"10.1016\/j.bbr.2023.114614_bib13","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/npp.2012.64","article-title":"Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist","volume":"37","author":"Horiguchi","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2023.114614_bib14","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.bbr.2015.08.040","article-title":"Prolonged reversal of the phencyclidine-induced impairment in novel object recognition by a serotonin (5-HT)1A-dependent mechanism","volume":"301","author":"Horiguchi","year":"2016","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bbr.2023.114614_bib15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bbr.2018.05.005","article-title":"Neurosteroid pregnenolone sulfate, alone, and as augmentation of lurasidone or tandospirone, rescues phencyclidine-induced deficits in cognitive function and social interaction","volume":"350","author":"Rajagopal","year":"2018","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bbr.2023.114614_bib16","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.schres.2018.04.006","article-title":"Identifying the genetic risk factors for treatment response to lurasidone by genome-wide association study: a meta-analysis of samples from three independent clinical trials","volume":"199","author":"Li","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbr.2023.114614_bib17","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.schres.2017.04.009","article-title":"Genetic predictors of antipsychotic response to lurasidone identified in a genome wide association study and by schizophrenia risk genes","volume":"192","author":"Li","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbr.2023.114614_bib18","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.neubiorev.2014.03.001","article-title":"Controversies on the role of 5-HT(2C) receptors in the mechanisms of action of antidepressant drugs","volume":"42","author":"Martin","year":"2014","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"16","key":"10.1016\/j.bbr.2023.114614_bib19","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.2174\/1568026619666190709101449","article-title":"Targeting the 5-HT2C receptor in biological context and the current state of 5-HT2C receptor ligand development","volume":"19","author":"Wold","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"issue":"4","key":"10.1016\/j.bbr.2023.114614_bib20","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00221-013-3508-2","article-title":"Multiple controls exerted by 5-HT2C receptors upon basal ganglia function: from physiology to pathophysiology","volume":"230","author":"De Deurwaerdere","year":"2013","journal-title":"Exp. Brain Res."},{"issue":"7","key":"10.1016\/j.bbr.2023.114614_bib21","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1021\/acschemneuro.5b00025","article-title":"Therapeutic potential of 5-HT2C receptor agonists for addictive disorders","volume":"6","author":"Higgins","year":"2015","journal-title":"ACS Chem. Neurosci."},{"issue":"1","key":"10.1016\/j.bbr.2023.114614_bib22","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1124\/pr.114.009514","article-title":"Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder","volume":"67","author":"Howell","year":"2015","journal-title":"Pharm. Rev."},{"issue":"17","key":"10.1016\/j.bbr.2023.114614_bib23","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1007\/s00213-015-3982-2","article-title":"Role of 5-HT(2)C receptors in effects of monoamine releasers on intracranial self-stimulation in rats","volume":"232","author":"Bauer","year":"2015","journal-title":"Psychopharmacol. (Berl.)"},{"issue":"3","key":"10.1016\/j.bbr.2023.114614_bib24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.pbb.2003.12.002","article-title":"Anxiolytic properties of the antipsychotic alkaloid alstonine","volume":"77","author":"Costa-Campos","year":"2004","journal-title":"Pharm. Biochem. Behav."},{"issue":"2\u20133","key":"10.1016\/j.bbr.2023.114614_bib25","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jep.2004.03.056","article-title":"Lack of pro-convulsant activity of the antipsychotic alkaloid alstonine","volume":"93","author":"Costa-Campos","year":"2004","journal-title":"J. Ethnopharmacol."},{"issue":"5","key":"10.1016\/j.bbr.2023.114614_bib26","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1017\/S1461145707007547","article-title":"Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis","volume":"10","author":"De Luca","year":"2007","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.bbr.2023.114614_bib27","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3389\/fpsyt.2019.00058","article-title":"Association of serotonin(2c) receptor polymorphisms with antipsychotic drug response in schizophrenia","volume":"10","author":"Li","year":"2019","journal-title":"Front. Psychiatry"},{"issue":"7","key":"10.1016\/j.bbr.2023.114614_bib28","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/oby.22789","article-title":"Lorcaserin departs, leaving more questions than answers","volume":"28","author":"Kumar","year":"2020","journal-title":"Obes. (Silver Spring)"},{"issue":"12","key":"10.1016\/j.bbr.2023.114614_bib29","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1038\/s41386-018-0160-3","article-title":"TPA-023 attenuates subchronic phencyclidine-induced declarative and reversal learning deficits via GABA(A) receptor agonist mechanism: possible therapeutic target for cognitive deficit in schizophrenia","volume":"43","author":"Rajagopal","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2023.114614_bib30","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.bbr.2015.10.044","article-title":"Nicotinic receptors and lurasidone-mediated reversal of phencyclidine-induced deficit in novel object recognition","volume":"301","author":"Miyauchi","year":"2016","journal-title":"Behav. Brain Res."},{"issue":"3","key":"10.1016\/j.bbr.2023.114614_bib31","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1021\/acs.jmedchem.0c01887","article-title":"Beta-carboline as a privileged scaffold for multitarget strategies in Alzheimer's disease therapy","volume":"64","author":"Beato","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbr.2023.114614_bib32","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ejmech.2018.08.027","article-title":"Beta-carboline alkaloid monomers and dimers: occurrence, structural diversity, and biological activities","volume":"157","author":"Dai","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"1\u20132","key":"10.1016\/j.bbr.2023.114614_bib33","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejphar.2005.07.002","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol","volume":"519","author":"Hashimoto","year":"2005","journal-title":"Eur. J. Pharm."},{"issue":"1","key":"10.1016\/j.bbr.2023.114614_bib34","first-page":"206","article-title":"Chance orders of alternating stimuli in visual discrimination experiments","volume":"42","author":"Gellermann","year":"1933","journal-title":"Pedagog. Semin. J. Genet. Psychol."},{"key":"10.1016\/j.bbr.2023.114614_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2021.113710","article-title":"Pimavanserin augments the efficacy of atypical antipsychotic drugs in a mouse model of treatment-refractory negative symptoms of schizophrenia","volume":"422","author":"Rajagopal","year":"2022","journal-title":"Behav. Brain Res."},{"issue":"2","key":"10.1016\/j.bbr.2023.114614_bib36","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.bbr.2007.10.012","article-title":"Efficacy of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats--a preliminary investigation","volume":"187","author":"Snigdha","year":"2008","journal-title":"Behav. Brain Res."},{"issue":"1","key":"10.1016\/j.bbr.2023.114614_bib37","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbr.2008.03.018","article-title":"Improvement of phencyclidine-induced social behaviour deficits in rats: involvement of 5-HT1A receptors","volume":"191","author":"Snigdha","year":"2008","journal-title":"Behav. Brain Res."},{"issue":"3","key":"10.1016\/j.bbr.2023.114614_bib38","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nrd746","article-title":"Allosteric binding sites on cell-surface receptors: novel targets for drug discovery","volume":"1","author":"Christopoulos","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.bbr.2023.114614_bib39","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1471-4159.2008.05789.x","article-title":"Endogenous serotonin and serotonin2C receptors are involved in the ability of M100907 to suppress cortical glutamate release induced by NMDA receptor blockade","volume":"108","author":"Calcagno","year":"2009","journal-title":"J. Neurochem."},{"issue":"12","key":"10.1016\/j.bbr.2023.114614_bib40","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.biopsych.2008.12.007","article-title":"Baseline and amphetamine-stimulated dopamine activity are related in drug-naive schizophrenic subjects","volume":"65","author":"Abi-Dargham","year":"2009","journal-title":"Biol. Psychiatry"},{"issue":"17","key":"10.1016\/j.bbr.2023.114614_bib41","doi-asserted-by":"crossref","first-page":"9235","DOI":"10.1073\/pnas.93.17.9235","article-title":"Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects","volume":"93","author":"Laruelle","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbr.2023.114614_bib42","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0079-6123(08)00909-6","article-title":"In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems","volume":"172","author":"Meltzer","year":"2008","journal-title":"Prog. Brain Res."},{"issue":"1\u20133","key":"10.1016\/j.bbr.2023.114614_bib43","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejphar.2010.10.094","article-title":"5-HT(2A) and 5-HT(2C) receptor stimulation are differentially involved in the cortical dopamine efflux-Studied in 5-HT(2A) and 5-HT(2C) genetic mutant mice","volume":"652","author":"Huang","year":"2011","journal-title":"Eur. J. Pharm."},{"issue":"3","key":"10.1016\/j.bbr.2023.114614_bib44","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00213-011-2207-6","article-title":"Pharmacological and behavioral characterization of the 5-HT2A receptor in C57BL\/6N mice","volume":"215","author":"Dougherty","year":"2011","journal-title":"Psychopharmacol. (Berl.)"},{"issue":"4","key":"10.1016\/j.bbr.2023.114614_bib45","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.bcp.2005.11.007","article-title":"Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms","volume":"71","author":"Zhang","year":"2006","journal-title":"Biochem. Pharm."},{"issue":"4","key":"10.1016\/j.bbr.2023.114614_bib46","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2174\/138161212799316217","article-title":"From the prodrome to chronic schizophrenia: the neurobiology underlying psychotic symptoms and cognitive impairments","volume":"18","author":"Howes","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bbr.2023.114614_bib47","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jpsychires.2014.02.012","article-title":"A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia","volume":"53","author":"Shen","year":"2014","journal-title":"J. Psychiatr. Res."},{"issue":"4","key":"10.1016\/j.bbr.2023.114614_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/psp.2014.7","article-title":"Prediction of efficacy of vabicaserin, a 5-HT2C agonist, for the treatment of schizophrenia using a quantitative systems pharmacology model","volume":"3","author":"Liu","year":"2014","journal-title":"CPT Pharmacomet. Syst. Pharm."},{"issue":"2","key":"10.1016\/j.bbr.2023.114614_bib49","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0893-133X(98)00004-9","article-title":"Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion","volume":"19","author":"Jentsch","year":"1998","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.bbr.2023.114614_bib50","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0893-133X(97)00034-1","article-title":"Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat","volume":"17","author":"Jentsch","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2023.114614_bib51","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.pbb.2014.08.006","article-title":"Responding for a conditioned reinforcer, and its enhancement by nicotine, is blocked by dopamine receptor antagonists and a 5-HT(2C) receptor agonist but not by a 5-HT(2A) receptor antagonist","volume":"125","author":"Guy","year":"2014","journal-title":"Pharm. Biochem. Behav."},{"issue":"2","key":"10.1016\/j.bbr.2023.114614_bib52","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0014-2999(99)00706-2","article-title":"Effects of RO 60 0175, a 5-HT(2C) receptor agonist, in three animal models of anxiety","volume":"387","author":"Kennett","year":"2000","journal-title":"Eur. J. Pharm."},{"issue":"13","key":"10.1016\/j.bbr.2023.114614_bib53","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1523\/JNEUROSCI.0112-04.2004","article-title":"Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens","volume":"24","author":"De Deurwaerdere","year":"2004","journal-title":"J. Neurosci."},{"issue":"8","key":"10.1016\/j.bbr.2023.114614_bib54","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0028-3908(99)00047-7","article-title":"SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system","volume":"38","author":"Di Matteo","year":"1999","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.bbr.2023.114614_bib55","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0893-133X(01)00268-8","article-title":"Gamma vinyl-GABA differentially modulates NMDA antagonist-induced increases in mesocortical versus mesolimbic DA transmission","volume":"25","author":"Schiffer","year":"2001","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.bbr.2023.114614_bib56","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0014-2999(97)01435-0","article-title":"Involvement of gamma-aminobutyric acid neurotransmission in phencyclidine-induced dopamine release in the medial prefrontal cortex","volume":"341","author":"Yonezawa","year":"1998","journal-title":"Eur. J. Pharm."},{"issue":"2","key":"10.1016\/j.bbr.2023.114614_bib57","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1124\/jpet.104.075382","article-title":"WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity","volume":"313","author":"Dunlop","year":"2005","journal-title":"J. Pharm. Exp. Ther."},{"issue":"1","key":"10.1016\/j.bbr.2023.114614_bib58","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1124\/jpet.106.106989","article-title":"WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity","volume":"320","author":"Marquis","year":"2007","journal-title":"J. Pharm. Exp. Ther."},{"issue":"1","key":"10.1016\/j.bbr.2023.114614_bib59","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.pnpbp.2011.08.022","article-title":"5-HT2A\/C receptors mediate the antipsychotic-like effects of alstonine","volume":"36","author":"Linck","year":"2012","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.bbr.2023.114614_bib60","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00213-010-1784-0","article-title":"The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen","volume":"209","author":"Canal","year":"2010","journal-title":"Psychopharmacol. (Berl.)"},{"issue":"2","key":"10.1016\/j.bbr.2023.114614_bib61","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0022-3565(24)36840-5","article-title":"Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats","volume":"282","author":"Willins","year":"1997","journal-title":"J. Pharm. Exp. Ther."},{"issue":"11","key":"10.1016\/j.bbr.2023.114614_bib62","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1038\/npp.2017.52","article-title":"5-HT(2C) agonists modulate schizophrenia-like behaviors in mice","volume":"42","author":"Pogorelov","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.bbr.2023.114614_bib63","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0092-8674(00)81972-8","article-title":"Mice with reduced NMDA receptor expression display behaviors related to schizophrenia","volume":"98","author":"Mohn","year":"1999","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.bbr.2023.114614_bib64","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/npp.2015.196","article-title":"Effects of beta-arrestin-biased dopamine D2 receptor ligands on schizophrenia-like behavior in hypoglutamatergic mice","volume":"41","author":"Park","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.bbr.2023.114614_bib65","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/gbb.12183","article-title":"NMDA receptor-deficient mice display sexual dimorphism in the onset and severity of behavioural abnormalities","volume":"13","author":"Milenkovic","year":"2014","journal-title":"Genes Brain Behav."},{"issue":"11","key":"10.1016\/j.bbr.2023.114614_bib66","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1586\/erc.09.123","article-title":"Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease","volume":"7","author":"Bays","year":"2009","journal-title":"Expert Rev. Cardiovasc Ther."},{"issue":"2","key":"10.1016\/j.bbr.2023.114614_bib67","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1021\/jm0709034","article-title":"Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity","volume":"51","author":"Smith","year":"2008","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bbr.2023.114614_bib68","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1124\/jpet.107.133348","article-title":"Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization","volume":"325","author":"Thomsen","year":"2008","journal-title":"J. Pharm. Exp. Ther."},{"issue":"3","key":"10.1016\/j.bbr.2023.114614_bib69","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJMoa0909809","article-title":"Multicenter, placebo-controlled trial of lorcaserin for weight management","volume":"363","author":"Smith","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bbr.2023.114614_bib70","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.cmet.2018.07.017","article-title":"Nucleus of the Solitary Tract Serotonin 5-HT(2C) receptors modulate food intake","volume":"28","author":"D'Agostino","year":"2018","journal-title":"Cell Metab."},{"issue":"6522","key":"10.1016\/j.bbr.2023.114614_bib71","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/374542a0","article-title":"Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors","volume":"374","author":"Tecott","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.bbr.2023.114614_bib72","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/978-3-642-25758-2_6","article-title":"5-HT(2C) agonists as therapeutics for the treatment of schizophrenia","volume":"213","author":"Rosenzweig-Lipson","year":"2012","journal-title":"Handb. Exp. Pharm."}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432823003327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432823003327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T13:40:46Z","timestamp":1759066846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166432823003327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":72,"alternative-id":["S0166432823003327"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2023.114614","relation":{},"ISSN":["0166-4328"],"issn-type":[{"type":"print","value":"0166-4328"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NU-1223, a simplified analog of alstonine, with 5-HT2cR agonist-like activity, rescues memory deficit and positive and negative symptoms in subchronic phencyclidine mouse model of schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2023.114614","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114614"}}